This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Bayer: last-minute presentations at ESMO congress CF
Veeva Systems: leader in cloud solutions for the life sciences industry Our Logo
Bayer's bottoming out continues to take shape - BofA commentary DP
Bayer gains significantly - focus on US glyphosate dispute DP
Bayer: new data for menopause treatment CF
Bayer: will present new data at ESMO CF
WDH: Fewer crop protection products planned for fields DP
Bayer to Unveil New Data from its Phase III OASIS 3 Long-Term Study of Elinzanetant in the Treatment of Vasomotor Symptoms Associated with Menopause CI
Expert dialog recommends restructuring EU agricultural policy DP
Bayer: FDA approval for investigational drug CF
US will still pay at least twice as much after negotiating drug prices RE
Transcript : Bayer Aktiengesellschaft Presents at Barclays 17th Annual Global Consumer Staples Conference, Sep-03-2024
Transcript : Bayer Aktiengesellschaft - Special Call
Bayer: positive study on finerenone in cardiology CF
Goldman rates Bayer 'Neutral' - Target 30 euros DP
BAYER AG : Goldman Sachs remains Neutral ZD
BAYER AG : JP Morgan gives a Neutral rating ZD
BAYER AG : UBS reiterates its Neutral rating ZD
Bayer in demand - Analyst: Kerendia result sufficient for approval DP
Bayer's Finerenone Treatment Shows Promising Results in Heart Failure Patients MT
Bayer Announces Late-Breaking KERENDIA® Investigational Data Presented CI
German Inflation's Cooling Surprise Boosts Local Shares MT
Bayer: new CEO for Bayer HealthCare in France CF
Bayer: first patient enrolled in phase III trial CF
Bayer to Present Phase III Kerendia Data CI
Chart Bayer AG
More charts
Logo Bayer AG
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Employees
96,567
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
28.91EUR
Average target price
35.59EUR
Spread / Average Target
+23.11%
Consensus
  1. Stock Market
  2. Equities
  3. BAYN Stock
  4. News Bayer AG
  5. Bayer's Monsanto Reaches $160 Million Settlement with Seattle in PCB Contamination Case